Waning of anti-HAV immunity in Shijiazhuang prefecture, Hebei province, China: A comparison of seroprevalence between 1992 and 2011

Chen, Ying; Zhang, Xinjiang; Zhao, Yuliang; Zhang, Yanhong; Wang, Songmei; Hao, Zhi-Yong; Zhang, Zhiyong; Ma, Jingjiao; Fang, Yun; Wang, Xuanyi

doi:10.1016/j.vaccine.2014.09.022

Cited by 10 publications

(11 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Consistent with previous serosurveillance data (Chen et al, 2014;Lee et al, 2011;Gallone et al, 2017), a continuous high level and no change in anti-HAV seroprevalence was found for the older population (>30 years of age) in the 2006 and 2014 surveys. This is explained by the fact that these older people were more likely to have been exposed to HAV due to poorer hygiene and sanitation during early childhood, at a time when the disease was endemic in China.…”

Section: Discussionsupporting

confidence: 90%

“…Passive antibody transfer is able to convey protection to the infants when exposed to HAV in early life. However, this protection is transient because of the rapid decline in acquired maternal antibodies with age (Chen et al, 2014). In 2008, HepA was implemented nationwide in China as part of the EPI, and since then Shandong has progressively provided free L-HepA for the target population of children throughout the province.…”

Section: Discussionmentioning

confidence: 99%

“…A population-based national survey conducted in 1992-1995 demonstrated that the overall seroprevalence of HAV-specific antibodies was 80.9% in China (Dai and Qi, 1997). With improvements in hygiene and socioeconomic conditions, an associated dynamic shift in HAV endemicity from high to intermediate has been documented over the past few decades in China (Chen et al, 2014).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Changes in seroprevalence of hepatitis A after the implementation of universal childhood vaccination in Shandong Province, China: A comparison between 2006 and 2014

Yan

Liu

et al. 2019

International Journal of Infectious Diseases

View full text Add to dashboard Cite

Objectives: The hepatitis A vaccine (HepA) has been included in the national expanded program on immunization (EPI) in China since 2008. This study was performed to evaluate the change in dynamics of the seroepidemiology of hepatitis A virus (HAV) before and after the introduction of the program. Methods: The trends in seroepidemiology of anti-HAV antibodies were examined in Shandong Province, China, drawing on two population-based samples of persons aged 1-59 years, one obtained in the year 2006 (n = 6682) and the other in 2014 (n = 5095). Results: A dramatic increase in seroprevalence of anti-HAV antibodies from 30.76% (95% confidence interval (CI) 26.24-35.28%) to 77.46% (95% CI 74.04-80.87%) among children aged 1.5-7 years (born after HepA was recommended for routine childhood immunization), as well as an increase from 35.32% (95% CI 29.31-41.33%) to 66.69% (95% CI 55.59-77.80%) in subjects aged 8-14 years, was observed in 2014 when compared with 2006. By contrast, a decline in seroprevalence among subjects aged 15-29 years, as seen particularly in those 20-29 years of age, from 85.72% (95% CI 80.29-91.14%) to 69.24% (95% CI 62.02-76.45%), was found in this study. There was no statistically significant difference in seroprevalence between 2006 and 2014 among the subjects older than 30 years of age. Conclusions: The national HepA routine immunization program has had a positive effect, leading to an increase in anti-HAV seroprevalence among children in Shandong Province, China. More attention should be paid to young adults in the province.

show abstract

Section: Discussionsupporting

confidence: 90%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Changes in seroprevalence of hepatitis A after the implementation of universal childhood vaccination in Shandong Province, China: A comparison between 2006 and 2014

Yan

Liu

et al. 2019

International Journal of Infectious Diseases

View full text Add to dashboard Cite

show abstract

“…The epidemiology of acute HAV disease varies worldwide and is in transition in many areas (8)(9)(10)(11)(12). In regions where HAV infection has been considered endemic (e.g., Africa, Asia, Central and South America, and Eastern Europe), up to 90% of children are infected by age 10 years (13).…”

Section: Introductionmentioning

confidence: 99%

Progress Toward Eliminating Hepatitis A Disease in the United States

et al. 2016

View full text Add to dashboard Cite

Summary Hepatitis A virus (HAV) disease disproportionately affects adolescents and young adults, American Indian/Alaska Native and Hispanic racial/ethnic groups, and disadvantaged populations. During 1996-2006, the Advisory Committee on Immunization Practices (ACIP) made incremental changes in hepatitis A (HepA) vaccination recommendations to increase coverage for children and persons at high risk for HAV infection. This report examines the temporal association of ACIP-recommended HepA vaccination and disparities (on the absolute scale) in cases of HAV disease and on seroprevalence of HAV-related protection (measured as antibody to HAV [anti-HAV]). ACIP-recommended childhood HepA vaccination in the United States has eliminated most absolute disparities in HAV disease by age, race/ethnicity, and geographic area with relatively modest ≥1-dose and ≥2-dose vaccine coverage. However, the increasing proportion of cases of HAV disease among adults with identified and unidentified sources of exposure underscores the importance of considering new

show abstract

“…In countries with growing economies and improving living conditions, where an epidemiologic shift from high to intermediate HAV incidence may evolve rapidly, hepatitis A control programs may need to consider the age of hepatitis A vaccine initiation based on maternal anti‐HAV prevalence and the likelihood of HAV exposure during early childhood . We found that children in group 1 who received vaccination starting at age 6 months consistently had lower anti‐HAV GMCs than group 2 and 3 children during follow‐up.…”

Section: Discussionmentioning

confidence: 79%

Persistence of seropositivity among persons vaccinated for hepatitis A during infancy by maternal antibody status: 15‐year follow‐up

et al. 2016

View full text Add to dashboard Cite

The effect of passively transferred maternal antibody to hepatitis A virus (anti‐HAV) on the duration of seropositivity after hepatitis A vaccination during infancy and early childhood is unclear. We obtained levels of anti‐HAV at intervals through age 15‐16 years among three groups of Alaskan Native children who initiated a two‐dose inactivated hepatitis A vaccination series at ages 6 months (group 1), 12 months (group 2), and 15 months (group 3), each group randomized according to maternal anti‐HAV status. Seropositivity (anti‐HAV ≥20 mIU/mL) 30 years after the second vaccine dose among the three groups was predicted using a random effects model. One hundred eighty‐three children participated in the study; follow‐up did not differ significantly by vaccine group or maternal anti‐HAV status. Although the frequency of seropositivity among all participants through age 10 years was high (100% among groups 2 and 3 and >90% among group 1), there was a decrease thereafter through age 15‐16 years among group 1 children, who initiated vaccination at age 6 months (50%‐75%), and among maternal anti‐HAV‐positive children in groups 2 and 3 (67%‐87%), who initiated vaccination at ages 12 months and 15 months, respectively. Nonetheless, the model indicated that anti‐HAV seropositivity should persist for ≥30 years after vaccination in 64% of all participants; among those seropositive at age 15‐16 years, 84% were predicted to remain so for ≥30 years. Conclusion: Most children vaccinated during early childhood available for sampling maintained seropositivity through age 15‐16 years; however, seropositivity was less frequent among those starting vaccination at age 6 months and among maternal antibody‐positive participants who started vaccination at age 12 months or 15 months; overall, our findings support current vaccine recommendations and continued follow‐up of this cohort. (Hepatology 2016;63:703–711)

show abstract

Waning of anti-HAV immunity in Shijiazhuang prefecture, Hebei province, China: A comparison of seroprevalence between 1992 and 2011

Cited by 10 publications

References 20 publications

Changes in seroprevalence of hepatitis A after the implementation of universal childhood vaccination in Shandong Province, China: A comparison between 2006 and 2014

Changes in seroprevalence of hepatitis A after the implementation of universal childhood vaccination in Shandong Province, China: A comparison between 2006 and 2014

Progress Toward Eliminating Hepatitis A Disease in the United States

Persistence of seropositivity among persons vaccinated for hepatitis A during infancy by maternal antibody status: 15‐year follow‐up

Contact Info

Product

Resources

About